• Home
  • About
  • Services
    • Research & Development
    • Manufacturing
      • Liquid Dose Manufacturing
      • Solid Dose Manufacturing
    • Packaging
    • Quality Assurance
  • Facilities
  • News
    • White Paper: The Promise of Gummies as a Drug Delivery System
    • White Paper: Flavor Masking for Rx and OTC Drugs
  • Contact
  • FAQs
PLD Pharma Services
Menu
  • Home
  • About
  • Services
    • Research & Development
    • Manufacturing
      • Liquid Dose Manufacturing
      • Solid Dose Manufacturing
    • Packaging
    • Quality Assurance
  • Facilities
  • News
    • White Paper: The Promise of Gummies as a Drug Delivery System
    • White Paper: Flavor Masking for Rx and OTC Drugs
  • Contact
  • FAQs

PLD Purchases Teva’s OTC Portfolio

September 19, 2019 / 5724 /10 comments

On June 28, 2019 PL Developments, the parent company of PLD Pharma Services, bought the U.S. store-brand, over-the-counter medicine division of Teva, which is headquartered in Israel. The transaction gives PLD entry into the market for nicotine gum, lozenges and patches that are approved by the U.S. Food and Drug Administration. The nicotine gum operations will complement the company’s existing nicotine lozenges business, giving PLD one of the most comprehensive portfolios of the high value nicotine replacement therapy (NRT) space.

The 93,000-square-foot plant in Copiague that comes with the deal is home to one of only three nicotine-gum manufacturing lines in the world (and the only in the US) to be certified by the by the FDA. More than 80 people work at the factory, which PLD will keep open.

Besides smoking cessation products, Singer said the Teva deal features 41 approved and pending products including: analgesics, cough and cold remedies, first aid ointments and the first store-brand alternative for Abreva, the cold sore cream, generic versions of Rogaine products, Claritin D and others.

The Teva products and plant will “strengthen our leadership position in supplying U.S. retailers with high-quality products in their own brands across a multitude of consumer health care categories,” according to Evan Singer, PLD President. “The acquisition reinforces PLD’s position as the second largest packager and distributor of U.S. store-brand drugs.”

Tags CDMO, FDA-Approved Products, Pharma Packaging, Pharmaceutical Industry, Pharmaceutical Manufacturing, PL Developments, PLD Pharma Services, R&D Development
Share Post
Previous
PLD Pharma Services to Exhibit at CPhI North America 2019
Next
Free Webinar! Lessons Learned: Choosing & Managing a CDMO

About Author

Avema

Other posts by Avema

Related posts

PLD Pharma Services to Exhibit at CPhI North America

April 9, 2018 / 4751 /8 comments

Visit the CDMO at Booth #1636 Westbury, NY – April 5, 2018 – PLD Pharma Services, a Contract Development Manufacturing Organization (CDMO) powered by PL…

Continue reading

10 Comments

  • canadian pharmacy viagra generic

    April 17, 2025 - 10:32 pm

    My relatives every time say that I am wasting my time here at web, except I know I am getting know-how every day by reading thes fastidious posts.

  • Bob4999

    April 21, 2025 - 11:02 am

    Very good https://is.gd/tpjNyL

  • Simon1246

    April 27, 2025 - 5:42 am

    Very good https://t.ly/tndaA

  • Ellis2201

    May 23, 2025 - 8:38 pm

    Awesome https://shorturl.fm/5JO3e

  • Elmer3122

    May 24, 2025 - 7:22 pm

    https://shorturl.fm/YvSxU

  • Sierra2741

    May 26, 2025 - 2:02 pm

    https://shorturl.fm/j3kEj

  • Geoff4081

    May 28, 2025 - 9:08 pm

    https://shorturl.fm/m8ueY

  • Billie851

    May 28, 2025 - 9:49 pm

    https://shorturl.fm/m8ueY

  • Ginger729

    June 1, 2025 - 8:05 am

    https://shorturl.fm/fSv4z

  • Frederick3829

    June 1, 2025 - 10:11 pm

    https://shorturl.fm/YZRz9

Leave a reply Cancel reply

HomeAbout UsServicesFacilitiesContact UsFaqs
© 2023. All Rights Reserved
Contact: 1.516.693.7384